All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
This month, in the European Journal of Surgical Oncology, L. Johnson from St. Bartholomew’s Hospital, London, UK, and colleagues published a report on the multi-disciplinary management of a UK series of Breast Implant Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL) and how the stage of disease can be used to guide treatment strategy.1
BIA-ALCL is a rare Non-Hodgkin Lymphoma of T-cell origin that occurs in the capsule of breast implants and has been given its own designation by the World Health Organization (WHO).2 It presents as a recurrent effusion in 80% of cases or a solid capsule-related mass in the remaining 20% of cases; diagnosis is achieved by identification of abnormal cells in an aspirate/biopsy that are CD30+ and ALK–.1,3 A new BIA-ALCL specific staging system states that stage I disease remains confined to the effusion or a layer on the luminal side of the capsule and can be treated adequately with implant removal and total capsulectomy (surgical removal of scar tissue or capsule that has become thickened and hardened around a breast implant). Treatment of stage II (locally advanced) and stage III/IV disease (regional and distant spread) may involve adjuvant therapies.1,4 It has been reported that the median time from time of implant to ALCL presentation is approximately 10 years, and silicone- as well as saline-filled implants have been implicated.5
The first ever case was reported in 1997, and the U.S. Food and Drug Administration (FDA) identified the possible association between implants and the development of ALCL in 2011. The rate of diagnosis is rising, possibly due to increased implant use or growing awareness of this rare complication. The exact number of cases and incidence is difficult to ascertain due to limitations in world-wide reporting and a deficit in global implant sales data;1,6 Daphne de Jong et al. estimate incidence in The Netherlands to be 1–3 cases per 1 million breast implants per year.7 More robust epidemiological studies are needed and thus far the etiology of the disease is unknown. So far, the majority of data appears to indicate that BIA-ALCL is more common after the insertion of implants with textured surfaces compared to those with smooth surfaces.6
In the UK, it is obligatory to report all confirmed cases to the Medicines and Healthcare Products Regulatory Agency (MHRA). In the US, The Plastic Surgery Foundation (PSF), in partnership with the American Society of Plastic Surgeons (ASPS) and the FDA, are building a BIA-ALCL-specific database (PROFILE registry) for the collection and follow-up of worldwide cases; it is strongly recommended that confirmed cases are submitted to the registry, only upon patient consent.1
So far, in the UK there have been 23 reported cases of BIA-ALCL. In the retrospective publication by Johnson et al., they report a series of 18 BIA-ALCL cases that were diagnosed between 2012 and 2016 at 15 different UK centers.1
The authors elaborated that cases did not seem to cluster around a specific unit or geographical location, and so hypothesized that local factors may not affect BIA-ALCL development. The group also speculate that the delays in diagnosis of 7 patients in their series are probably due to lack of awareness. They state that their report makes up “part of a wider strategy to raise awareness through education and better information.”
Traditionally, Ann Arbour classification is used to stage ALCL, which the authors point out could potentially result in over-staging and treatment of more localized BIA-ALCL cases; the new BIA-ALCL specific staging system4 differentiates very low risk patients (localized intra-luminal disease) from higher risk patients (extra-luminal disease or masses) who appear to benefit from more aggressive systemic treatment. The group state that their findings support this new staging system.
The group recommend that confirmed cases should be managed in specialist tertiary centers, which have the appropriate knowledge and experience in managing BIA-ALCL. The group go on to express that “this will permit consolidation of clinical and research resources and will lead to a better understanding of lymphomagenesis in this context”.
The authors state that more prospective, national, observational studies are required in order to accumulate more complete data. They emphasize the relevance and importance of registries and consenting patients for inclusion. These databases will aid our understanding on the use of implants as well as the subsequent monitoring and collation of long-term after-effects that takes place.
Lastly, the group concludes that, although there is a very low risk of developing BIA-ALCL, “it is nevertheless our duty to inform any patient receiving a breast implant that there is a risk.”
BACKGROUND: Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, Non-Hodgkin lymphoma arising in the capsule of breast implants. BIA-ALCL presents as a recurrent effusion and/or mass. Tumours exhibit CD30 expression and are negative for Anaplastic Lymphoma Kinase (ALK). We report the multi-disciplinary management of the UK series and how the stage of disease may be used to stratify treatment.
METHODS: Between 2012 and 2016, 23 cases of BIA-ALCL were diagnosed in 15 regional centres throughout the UK. Data on breast implant surgeries, clinical features, treatment and follow-up were available for 18 patients.
RESULTS: The mean lead-time from initial implant insertion to diagnosis was 10 years (range: 3-16). All cases were observed in patients with textured breast implants or expanders. Fifteen patients with breast implants presented with stage I disease (capsule confined), and were treated with implant removal and capsulectomy. One patient received adjuvant chest-wall radiotherapy. Three patients presented with extra-capsular masses (stage IIA). In addition to explantation, capsulectomy and excision of the mass, all patients received neo-/adjuvant chemotherapy with CHOP as first line. One patient progressed on CHOP but achieved pathological complete response (pCR) with Brentuximab Vedotin. After a mean follow-up of 23 months (range: 1-56) all patients reported here remain disease-free.
DISCUSSION: BIA-ALCL is a rare neoplasm with a good prognosis. Our data support the recommendation that stage I disease be managed with surgery alone. Adjuvant chemotherapy may be required for more invasive disease and our experience has shown the efficacy of Brentuximab as a second line treatment.
New insights into the molecular pathogenesis of T-cell lymphomas
Over the last decade, whole-genome studies revealed that PTCLs originate from subsets of helper T (Th) cells and oncogenic events. However, the role of the tumor environment, immune...
Brentuximab vedotin plus CHP is approved by the European Commission and China for the treatment of adult patients with sALCL
On May 14, 2020, brentuximab vedotin in combination with cyclophosphamide, doxorubicin, prednisone (CHP) was granted an...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox